Bora Pharmaceuticals Co Ltd (保瑞藥業) has posted significant earnings gains in the year to date as the company’s acquisition efforts to solidify its foothold in the US contract manufacturing market begin to pay off, it said.
Net income in the second quarter rose 85 percent sequentially to NT$74 million (US$2.41 million), while revenue surged 245.61 percent to NT$394 million, company filings with the Taiwan Stock Exchange showed.
Earnings per share were NT$2.82, up from NT$1.56 at the end of March.
However, gross margin dropped to 30.4 percent in the second quarter, from 35.1 in the first quarter, with operating margin also dipping to 13.3 percent from 22.3 percent at the end of March.
In the first half of the year, total net income came to NT$113 million, compared with NT$4.1 million in the same period last year. Earnings per share jumped to NT$4.34, from NT$0.17.
Bora Pharmaceuticals in February completed a NT$550 million purchase of a Taiwan-based manufacturing facility previously owned by Impax Laboratories Inc.
Impax has merged into US-based Amneal Pharmaceuticals Inc to become one of the country’s largest makers of generic drugs, so Bora Pharmaceuticals was able to purchase the facility, valued at NT$3.5 billion, at a steep discount, company chairman Bobby Sheng (盛保熙) told an investors’ conference in March.
Through the purchase, the company has gained an advanced manufacturing facility certified by US regulators and customers, Sheng said.
The acquisition has helped Bora Pharmaceuticals expand its list of US customers to become one of Taiwan’s top-five makers of oral formulation drugs, the government-funded Institute for Biotechnology and Medicine Industry reported in a newsletter on Thursday, quoting Sheng.
The company’s contract manufacturing and development businesses now account for 49 percent of Taiwan’s drug exports to the US, Sheng was quoted as saying in the newsletter, adding that Bora Pharmaceuticals products are sold in more than 17 markets.
Contract manufacturing and development has seen faster growth as new-drug developers have increased their reliance on partners, due to difficulties in securing enough volume to sustain their own facilities, he said.
Increasingly, new-drug development companies are becoming “virtual,” with patents and regulatory approvals their most significant assets, Sheng said.
The company would continue to seek acquisition targets and joint development partnerships for new brand-name drugs with specialty pharmaceutical companies, he was quoted as saying.
The company’s strategy is to build up its brand power in the US and European markets before expanding to China, Sheng said.
The Eurovision Song Contest has seen a surge in punter interest at the bookmakers, becoming a major betting event, experts said ahead of last night’s giant glamfest in Basel. “Eurovision has quietly become one of the biggest betting events of the year,” said Tomi Huttunen, senior manager of the Online Computer Finland (OCS) betting and casino platform. Betting sites have long been used to gauge which way voters might be leaning ahead of the world’s biggest televised live music event. However, bookmakers highlight a huge increase in engagement in recent years — and this year in particular. “We’ve already passed 2023’s total activity and
Nvidia Corp CEO Jensen Huang (黃仁勳) today announced that his company has selected "Beitou Shilin" in Taipei for its new Taiwan office, called Nvidia Constellation, putting an end to months of speculation. Industry sources have said that the tech giant has been eyeing the Beitou Shilin Science Park as the site of its new overseas headquarters, and speculated that the new headquarters would be built on two plots of land designated as "T17" and "T18," which span 3.89 hectares in the park. "I think it's time for us to reveal one of the largest products we've ever built," Huang said near the
China yesterday announced anti-dumping duties as high as 74.9 percent on imports of polyoxymethylene (POM) copolymers, a type of engineering plastic, from Taiwan, the US, the EU and Japan. The Chinese Ministry of Commerce’s findings conclude a probe launched in May last year, shortly after the US sharply increased tariffs on Chinese electric vehicles, computer chips and other imports. POM copolymers can partially replace metals such as copper and zinc, and have various applications, including in auto parts, electronics and medical equipment, the Chinese ministry has said. In January, it said initial investigations had determined that dumping was taking place, and implemented preliminary
Intel Corp yesterday reinforced its determination to strengthen its partnerships with Taiwan’s ecosystem partners including original-electronic-manufacturing (OEM) companies such as Hon Hai Precision Industry Co (鴻海精密) and chipmaker United Microelectronics Corp (UMC, 聯電). “Tonight marks a new beginning. We renew our new partnership with Taiwan ecosystem,” Intel new chief executive officer Tan Lip-bu (陳立武) said at a dinner with representatives from the company’s local partners, celebrating the 40th anniversary of the US chip giant’s presence in Taiwan. Tan took the reins at Intel six weeks ago aiming to reform the chipmaker and revive its past glory. This is the first time Tan